Lurasidone

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. It is grouped under the following drug class(es): Psychotropic agents. Its therapeutic use is listed as antipsychotics, central nervous system (CNS) agents and mood stabilizers. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include lurasidona and lurasidonum. Its PubChem CID is 213046.

CAS No 367514-87-2
Molecular Formula C28H36N4O2S
Molecular Weight 492.70 g/mol
Synonyms (1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione

Frequently Asked Questions